| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
173,140,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Silverback Therapeutics is a biopharmaceutical company focused on utilizing its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Co. has engineered SBT8230 to treat chronic hepatitis B virus by eliciting an anti-viral immune response through targeting TLR8 activation to the liver. SBT8230 is comprised of an ASGR1 monoclonal antibody conjugated to the same TLR8 linker-payload as SBT6050, but with an average drug antibody ratio (DAR) of about two as opposed to the average DAR of about four used in SBT6050.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,401,299 |
1,401,299 |
8,937,557 |
8,945,807 |
| Total Buy Value |
$13,289,411 |
$13,289,411 |
$51,242,891 |
$51,294,397 |
| Total People Bought |
1 |
1 |
4 |
5 |
| Total Buy Transactions |
3 |
3 |
9 |
10 |
| Total Shares Sold |
1,206,520 |
1,206,520 |
1,606,520 |
1,750,416 |
| Total Sell Value |
$11,094,300 |
$11,094,300 |
$13,904,016 |
$14,684,595 |
| Total People Sold |
2 |
2 |
3 |
3 |
| Total Sell Transactions |
26 |
26 |
37 |
40 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shawver Laura |
Director |
– • – |
2023-07-06 |
4 |
OE |
$1.27 |
$42,558 |
D/D |
33,510 |
243,856 |
|
- |
|
| Shawver Laura |
Director |
– • – |
2023-07-05 |
4 |
AS |
$6.41 |
$199,552 |
D/D |
(31,112) |
210,346 |
|
- |
|
| Shawver Laura |
Director |
– • – |
2023-07-05 |
4 |
OE |
$1.27 |
$39,512 |
D/D |
31,112 |
241,458 |
|
- |
|
| Shawver Laura |
Director |
– • – |
2023-07-03 |
4 |
AS |
$6.73 |
$178,347 |
D/D |
(26,520) |
210,346 |
|
- |
|
| Shawver Laura |
Director |
– • – |
2023-07-03 |
4 |
OE |
$1.27 |
$33,680 |
D/D |
26,520 |
236,866 |
|
- |
|
| Shawver Laura |
Director |
– • – |
2023-06-02 |
4 |
AS |
$6.95 |
$187,240 |
D/D |
(26,941) |
210,346 |
|
- |
|
| Shawver Laura |
Director |
– • – |
2023-06-02 |
4 |
OE |
$1.27 |
$34,215 |
D/D |
26,941 |
237,287 |
|
- |
|
| Shawver Laura |
Director |
– • – |
2023-06-01 |
4 |
AS |
$6.80 |
$496,801 |
D/D |
(73,059) |
210,346 |
|
- |
|
| Shawver Laura |
Director |
– • – |
2023-06-01 |
4 |
OE |
$1.27 |
$92,785 |
D/D |
73,059 |
283,405 |
|
- |
|
| Tanimoto Sarina |
Chief Medical Officer |
• – • |
2023-05-17 |
4 |
GA |
$0.00 |
$0 |
I/I |
2,100,000 |
2,100,000 |
|
- |
|
| Tanimoto Sarina |
Chief Medical Officer |
• – • |
2023-05-17 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,050,000 |
4,126,822 |
|
- |
|
| Tanimoto Sarina |
Chief Medical Officer |
• – • |
2023-05-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,050,000 |
3,276,854 |
|
- |
|
| Lowenthal Richard E |
President and CEO |
• • • |
2023-05-17 |
4 |
GA |
$0.00 |
$0 |
I/I |
2,100,000 |
2,100,000 |
|
- |
|
| Lowenthal Richard E |
President and CEO |
• • • |
2023-05-17 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,050,000 |
3,276,854 |
|
- |
|
| Lowenthal Richard E |
President and CEO |
• • • |
2023-05-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,050,000 |
4,126,822 |
|
- |
|
| Shawver Laura |
Director |
– • – |
2023-05-09 |
4 |
AS |
$5.31 |
$227,799 |
D/D |
(42,900) |
210,346 |
|
- |
|
| Shawver Laura |
Director |
– • – |
2023-05-09 |
4 |
OE |
$1.27 |
$54,483 |
D/D |
42,900 |
253,246 |
|
- |
|
| Shawver Laura |
Director |
– • – |
2023-05-08 |
4 |
AS |
$6.16 |
$351,736 |
D/D |
(57,100) |
210,346 |
|
- |
|
| Shawver Laura |
Director |
– • – |
2023-05-08 |
4 |
OE |
$1.27 |
$72,517 |
D/D |
57,100 |
267,446 |
|
- |
|
| Scott Kathleen D. |
Chief Financial Officer |
• – – |
2022-11-29 |
4 |
B |
$6.24 |
$51,506 |
I/I |
8,250 |
8,250 |
1.99 |
- |
|
| Shawver Laura |
Director |
– • – |
2022-11-09 |
4 |
AS |
$4.58 |
$201,044 |
D/D |
(43,896) |
210,346 |
|
- |
|
| Deerfield Private Design Fund Iv, L.p. |
Director |
– • • |
2022-11-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
11,077,928 |
|
- |
|
| Chakma Justin |
Chief Business Officer |
• – – |
2022-11-08 |
4 |
A |
$0.00 |
$0 |
D/D |
236,380 |
236,380 |
|
- |
|
| Pratik Shah Living Trust Dated June 15, 2011 |
10% Owner |
– – • |
2022-11-08 |
4 |
A |
$0.00 |
$0 |
I/I |
10,156,204 |
10,156,204 |
|
- |
|
| Lowenthal Richard E |
President and CEO |
• • • |
2022-11-08 |
4 |
A |
$0.00 |
$0 |
I/I |
7,872,554 |
1,772,850 |
|
- |
|
116 Records found
|
|
Page 3 of 5 |
|
|
